Evotec (ETR:EVT) Stock Price Down 1.4% - Here's What Happened

Key Points

• Evotec SE's stock decreased by 1.4% during mid-day trading on Monday, with prices dropping to a low of €6.76 ($7.87) and closing at €6.95 ($8.08).
• Trading volume fell significantly, with approximately 663,097 shares changing hands, marking a 51% decline from the average daily volume of 1,360,000 shares.
• Evotec, which has a market capitalization of $1.25 billion, is involved in drug discovery and development across various therapeutic areas, including cancer, autoimmune diseases, and diabetes.

Evotec SE (ETR:EVT - ) was down 1.4% during mid-day trading on Monday . The company traded as low as €6.76 ($7.87) and last traded at €6.95 ($8.08). Approximately 663,097 shares changed hands during trading, a decline of 51% from the average daily volume of 1,360,000 shares. The stock had previously closed at €7.05 ($8.19).

Evotec Price Performance

The stock's fifty day moving average is €7.10 and its 200-day moving average is €7.18. The stock has a market capitalization of $1.25 billion, a PE ratio of -7.27, a P/E/G ratio of 0.98 and a beta of 1.05.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.